PT - JOURNAL ARTICLE AU - Habel, Jennifer R AU - Chua, Brendon Y AU - Kedzierski, Lukasz AU - Selva, Kevin J AU - Damelang, Timon AU - Haycroft, Ebene R AU - Nguyen, Thi HO AU - Koay, Hui-Fern AU - Nicholson, Suellen AU - McQuilten, Hayley AU - Jia, Xiaoxiao AU - Allen, Lilith F AU - Hensen, Luca AU - Zhang, Wuji AU - van de Sandt, Carolien E AU - Neil, Jessica A AU - Amanat, Fatima AU - Krammer, Florian AU - Wragg, Kathleen AU - Juno, Jennifer A AU - Wheatley, Adam K AU - Tan, Hyon-Xhi AU - Pell, Gabrielle AU - Audsley, Jennifer AU - Thevarajan, Irani AU - Denholm, Justin AU - Subbarao, Kanta AU - Godfrey, Dale I AU - Cheng, Allen C AU - Tong, Steven YC AU - Bond, Katherine AU - Williamson, Deborah A AU - James, Fiona AU - Holmes, Natasha E AU - Smibert, Olivia C AU - Trubiano, Jason A AU - Gordon, Claire L AU - Chung, Amy W AU - Whitehead, Clare L AU - Kent, Stephen J AU - Lappas, Martha AU - Rowntree, Louise C AU - Kedzierska, Katherine TI - Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation AID - 10.1101/2021.08.21.21262399 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.21.21262399 4099 - http://medrxiv.org/content/early/2021/08/23/2021.08.21.21262399.short 4100 - http://medrxiv.org/content/early/2021/08/23/2021.08.21.21262399.full AB - Although pregnancy poses a greater risk for severe COVID-19, the underlying immunological changes associated with SARS-CoV-2 infection during pregnancy are poorly understood. We defined immune responses to SARS-CoV-2 in pregnant and non-pregnant women during acute and convalescent COVID-19 up to 258 days post symptom onset, quantifying 217 immunological parameters. Additionally, matched maternal and cord blood were collected from COVID-19 convalescent pregnancies. Although serological responses to SARS-CoV-2 were similar in pregnant and non-pregnant women, cellular immune analyses revealed marked differences in key NK cell and unconventional T cell responses during COVID-19 in pregnant women. While NK cells, γδ T cells and MAIT cells displayed pre-activated phenotypes in healthy pregnant women when compared to non-pregnant age-matched women, activation profiles of these pre-activated NK and unconventional T cells remained unchanged at acute and convalescent COVID-19 in pregnancy. Conversely, activation dynamics of NK and unconventional T cells were prototypical in non-pregnant women in COVID-19. In contrast, activation of αβ CD4+ and CD8+ T cells, T follicular helper cells and antibody-secreting cells was similar in pregnant and non-pregnant women with COVID-19. Elevated levels of IL-1β, IFN-γ, IL-8, IL-18 and IL-33 were also found in pregnant women in their healthy state, and these cytokine levels remained elevated during acute and convalescent COVID-19. Collectively, our study provides the first comprehensive map of longitudinal immunological responses to SARS-CoV-2 infection in pregnant women, providing insights into patient management and education during COVID-19 pregnancy.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Fatima Amanat is also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.Funding StatementThis work was supported by the Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grant to KK (#1173871), Research Grants Council of the Hong Kong Special Administrative Region, China (#T11-712/19-N) to KK, the Jack Ma Foundation to KK, KS, DIG, IT and AWC, the Victorian Government MRFF award (#2002073) to SJK, DIG and AWC, MRFF Award (#1202445) to KK, MRFF Award (#2005544) to KK, SJK, AWC, ACC, DW and JAJ, NHMRC program grant 1149990 (SJK), NHMRC Program Grant (1113293) to DIG. THON was supported by a NHMRC Emerging Leadership Level 1 Investigator Grant (#1194036), HFK, CLG and JAT by NHMRC Early Career Fellowships (#1160333, #1160963 and #1139902), KS by a NHMRC Investigator grant (#1177174), DIG by a NHMRC Senior Principal Research Fellowship (#1117766), AWC by an NHMRC Career Development Fellowship (#1140509) and SJK by NHMRC Senior Principal Research Fellowship (#1136322). JRH, LH and WZ are supported by the Melbourne International Research Scholarship (MIRS) and the Melbourne International Fee Remission Scholarship (MIFRS) from The University of Melbourne. XJ was supported by China Scholarship Council-University of Melbourne joint Scholarship. JAJ is supported by an NHMRC Early Career Fellowship (ECF) (#1123673). KK and AWC were supported by the University of Melbourne Dame Kate Campbell Fellowship. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Alfred Hospital (#280/14), Melbourne Health (HREC/66341/MH-2020 and HREC/17/MH/53), Austin Health (HREC/63201/Austin-2020), Monash Health (HREC/15/MonH/64), Mercy Health (R14/25 and R04/29), Australian Red Cross Lifeblood (2015#08), and the University of Melbourne (#1442952, #1749349, #2056901, #1443540, #2056761, #1955465, 2020-20782-12450-1, 2021-13973-14410-3 and 2021-13973-14410-3) Human Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source data underlying Figures and Supplementary Figures will be provided as Source Data. Raw FACS data are shown in the manuscript. FACS-source files are available from the authors upon request.